Skip to main content
. 2024 May 7;14:1348343. doi: 10.3389/fonc.2024.1348343

Figure 1.

Figure 1

Metabolic and radiologic evaluation on FDG-PET of cancer lesions throughout Phesgo® treatment. (A) Obtained on July 22, 2022; showed disease progression with an increased atypical lesion in the right breast and bilateral lymphadenopathies. (B) Captured on January 10, 2023; demonstrated a favorable response to Phesgo® treatment with reduced breast lesion size and improved lymphadenopathies. (C) Obtained on April 20, 2023; indicated disease progression with new hypermetabolic foci, pleural effusion, ascites, and lytic lesions.